Literature DB >> 20936300

Early atrophy of pallidum and accumbens nucleus in Huntington's disease.

Simon J A van den Bogaard1, Eve M Dumas, Tanka P Acharya, Hans Johnson, Douglas R Langbehn, Rachael I Scahill, Sarah J Tabrizi, Mark A van Buchem, Jeroen van der Grond, Raymund A C Roos.   

Abstract

In Huntington's disease (HD) atrophy of the caudate nucleus and putamen has been described many years before clinical manifestation. Volume changes of the pallidum, thalamus, brainstem, accumbens nucleus, hippocampus, and amygdala are less well investigated, or reported with contradicting results. The aim of our study is to provide a more precise view of the specific atrophy of the subcortical grey matter structures in different stages of Huntington's disease, and secondly to investigate how this influences the clinical manifestations. All TRACK-HD subjects underwent standardised T1-weighted 3T MRI scans encompassing 123 manifest HD (stage 1, n = 77; stage 2, n = 46), 120 premanifest HD (close to onset n = 58, far from onset n = 62) and 123 controls. Using FMRIB's FIRST and SIENAX tools the accumbens nucleus, amygdala, brainstem, caudate nucleus, hippocampus, pallidum, putamen, thalamus and whole brain volume were extracted. Results showed that volumes of the caudate nucleus and putamen were reduced in premanifest HD far from predicted onset (>10.8 years). Atrophy of accumbens nucleus and pallidum was apparent in premanifest HD in the close to onset group (0-10.8 years). All other structures were affected to some degree in the manifest group, although brainstem, thalamus and amygdala were relatively spared. The accumbens nucleus, putamen, pallidum and hippocampus had a strong significant correlation with functional and motor scores. We conclude that volume changes may be a sensitive and reliable measure for early disease detection and in this way serve as a biomarker for Huntington's disease. Besides the caudate nucleus and putamen, the pallidum and the accumbens nucleus show great potential in this respect.

Entities:  

Mesh:

Year:  2010        PMID: 20936300      PMCID: PMC3112014          DOI: 10.1007/s00415-010-5768-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Normalized accurate measurement of longitudinal brain change.

Authors:  S M Smith; N De Stefano; M Jenkinson; P M Matthews
Journal:  J Comput Assist Tomogr       Date:  2001 May-Jun       Impact factor: 1.826

2.  Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.

Authors:  Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

3.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease.

Authors:  E H Aylward; A M Codori; A Rosenblatt; M Sherr; J Brandt; O C Stine; P E Barta; G D Pearlson; C A Ross
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

4.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.

Authors:  H D Rosas; N D Hevelone; A K Zaleta; D N Greve; D H Salat; B Fischl
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

5.  Striatal gray matter loss in Huntington's disease is leftward biased.

Authors:  Mark Mühlau; Christian Gaser; Afra M Wohlschläger; Adolf Weindl; Michael Städtler; Michael Valet; Claus Zimmer; Jan Kassubek; Alexander Peinemann
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

6.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.

Authors:  E H Aylward; A M Codori; P E Barta; G D Pearlson; G J Harris; J Brandt
Journal:  Arch Neurol       Date:  1996-12

7.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.

Authors:  G J Harris; G D Pearlson; C E Peyser; E H Aylward; J Roberts; P E Barta; G A Chase; S E Folstein
Journal:  Ann Neurol       Date:  1992-01       Impact factor: 10.422

8.  Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study.

Authors:  J Kassubek; F D Juengling; T Kioschies; K Henkel; J Karitzky; B Kramer; D Ecker; J Andrich; C Saft; P Kraus; A J Aschoff; A C Ludolph; G B Landwehrmeyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

9.  Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases.

Authors:  T L Jernigan; D P Salmon; N Butters; J R Hesselink
Journal:  Biol Psychiatry       Date:  1991-01-01       Impact factor: 13.382

10.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

View more
  54 in total

1.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

2.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.

Authors:  J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

3.  Microcirculation response to local cooling in patients with Huntington's disease.

Authors:  Ziva Melik; Jan Kobal; Ksenija Cankar; Martin Strucl
Journal:  J Neurol       Date:  2011-10-20       Impact factor: 4.849

4.  Genome-wide Analysis of RARβ Transcriptional Targets in Mouse Striatum Links Retinoic Acid Signaling with Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Anna Niewiadomska-Cimicka; Agnieszka Krzyżosiak; Tao Ye; Anna Podleśny-Drabiniok; Doulaye Dembélé; Pascal Dollé; Wojciech Krężel
Journal:  Mol Neurobiol       Date:  2016-07-12       Impact factor: 5.590

5.  Magnetization transfer imaging in premanifest and manifest Huntington disease.

Authors:  S J A van den Bogaard; E M Dumas; J Milles; R Reilmann; J C Stout; D Craufurd; M A van Buchem; J van der Grond; R A C Roos
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-12       Impact factor: 3.825

6.  Network spread determines severity of degeneration and disconnection in Huntington's disease.

Authors:  Govinda R Poudel; Ian H Harding; Gary F Egan; Nellie Georgiou-Karistianis
Journal:  Hum Brain Mapp       Date:  2019-06-12       Impact factor: 5.038

7.  Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Authors:  Lin Chen; Jun Hua; Christopher A Ross; Shuhui Cai; Peter C M van Zijl; Xu Li
Journal:  J Neurosci Res       Date:  2018-11-29       Impact factor: 4.164

8.  Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up.

Authors:  S J A van den Bogaard; E M Dumas; E P Hart; J Milles; R Reilmann; J C Stout; D Craufurd; C R Gibbard; S J Tabrizi; M A van Buchem; J van der Grond; R A C Roos
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-23       Impact factor: 3.825

9.  Altered membrane properties and firing patterns of external globus pallidus neurons in the R6/2 mouse model of Huntington's disease.

Authors:  Garnik Akopian; Joshua Barry; Carlos Cepeda; Michael S Levine
Journal:  J Neurosci Res       Date:  2016-09-12       Impact factor: 4.164

10.  Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis.

Authors:  Imis Dogan; Simon B Eickhoff; Jörg B Schulz; N Jon Shah; Angela R Laird; Peter T Fox; Kathrin Reetz
Journal:  Neurodegener Dis       Date:  2012-08-23       Impact factor: 2.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.